Patient Reported Outcome Measurement Within the Secured Access to Innovative Medicines for Children With cAncer (SACHA) Study (PRO-SACHA)

PRO-SACHA: Patient Reported Outcome Measurement Within the Secured Access to Innovative Medicines for Children With cAncer (SACHA) Study

Patient-Reported Outcomes (PROs) are patient-centered measures used to assess health status, track changes over time, and evaluate the impact of treatment on the patient's perceived health.

The SACHA study is a French prospective observational study developed by the Société Française de lutte contre les Cancers de l'Enfant et de l'adolescent (SFCE). It prospectively collects real-world safety and activity data on novel therapies given to patients aged 25 or younger with pediatric malignancies (solid tumors or hematologic malignancies) or related conditions, outside of a clinical trial.

The Symptom Screening in Pediatrics Tool (SSPedi) is a validated questionnaire for measuring patient-reported symptoms in pediatric oncology. It includes 15 questions covering common symptoms in pediatric cancer patients and one open-ended question allowing patients to report any other bothersome symptoms. Patients complete the questionnaire through an online application.

The PRO-SACHA study aims to describe the symptoms reported by participants receiving novel therapies in pediatric oncology and to examine the concordance between participant-reported symptoms and symptomatic adverse events (AEs) reported by investigators.

This prospective observational study evaluates patient-reported symptoms in patients aged 2 to 18 years enrolled in the SACHA study. Participation is voluntary, based on an opt-out consent model (French category 3 interventional research involving the human person).

Planned enrollment: 72 participants over 18 months, with each participant followed for 7 months (a 6-month follow-up period, with a 7th-month window for questionnaire completion). Participants are enrolled in PRO-SACHA at the same time as their enrollment in SACHA (two separate studies with separate enrollment).

SSPedi responses (a self-report questionnaire capturing symptoms experienced by patients) are collected electronically through an online application. The extracted, anonymized data are then correlated with adverse events reported by investigators. The concordance between participant-reported symptoms and adverse events recorded in SACHA (CTCAE grading) will be analyzed.

Study Overview

• Status: Not yet recruiting
• Conditions: CNS Tumor, Childhood
• Intervention / Treatment: Other: SSPedi - Symptom Screening in Pediatrics Questionnaire

• Study Type: Observational
• Enrollment (Estimated): 72

Contacts and Locations

• Study Contact: Name: Gabriel Revon-Rivière, Dr; Phone Number: 33 04 91 38 68 22; Email: gabriel.revon-riviere@ap-hm.fr

Study Locations

• France
  • Marseille, France
    • Assistance Publique - Hôpitaux de Marseille
    • Contact: Gabriel Revon-Rivière, Dr; Phone Number: 33 04 91 38 68 22; Email: gabriel.revon-riviere@ap-hm.fr

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Child; Adult
• Accepts Healthy Volunteers: No

• Sampling Method: Non-Probability Sample

Study Population

Participants are enrolled in PRO-SACHA at the same time as their enrollment in SACHA (two separate studies with separate enrollment).

SSPedi responses (a self-report questionnaire capturing symptoms experienced by patients) are collected electronically through an online application

Description

Inclusion Criteria:

• Aged 2 to 18 years
• Patients aged 8 to 18 years who can read French, English, or Spanish fluently OR patients aged 6 to 7 years who can read French, English, or Spanish fluently, OR patients aged 2 to 7 years who cannot read fluently but whose parents can read French, English, or Spanish fluently
• Patients included in the SACHA study before starting treatment
• Patients with a pediatric tumor or leukemia who have failed treatment or relapsed and have no standard treatment options available OR patients receiving first-line treatment with no standard treatment options available (e.g., inoperable plexiform neurofibroma and MEK inhibitors, infantile fibrosarcoma and NTRK inhibitors)
• Not eligible for an open early-phase clinical trial in France, or declining participation
• Treated with a new innovative medicinal product and discussed at a RCCPI meeting under a granted early access authorization or compassionate use authorization issued by the ANSM, or receiving off-label use of a medicinal product already authorized in adults
• Treated in one of the SFCE centers authorized to prescribe chemotherapy
• The holders of parental authority have stated their non-opposition to their child's participation in the study after being informed. Minors will receive age-appropriate information adapted to their level of understanding. If the minor is emancipated, they will provide non-opposition directly
• A patient who is prescribed another innovative therapy and is re-included in SACHA may be included again in PRO-SACHA

Exclusion Criteria:

• Patient who has already started the innovative treatment
• Patients aged 8 years and older who cannot read
• Patients whose clinical condition does not allow them to report symptoms themselves (i.e., non-communicative patient; judgment left to the investigator's discretion)
• Patients currently enrolled in an early-phase trial
• Refusal of participation by the patient or their legal representatives
• Patient unable to express consent to participate in the study

Study Plan

How is the study designed?

Number of groups / cohorts

1

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
Pediatric cancer cohort	Other: SSPedi - Symptom Screening in Pediatrics Questionnaire; SSPedi responses (a self-report questionnaire capturing symptoms experienced by patients) are collected electronically through an online application

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Score of the Symptom Screening in Pediatrics Questionnaire (SSPedi)	Measure of the Symptom Screening in Pediatrics Questionnaire (SSPedi) scores for each patient, values ranging from 0 to 60, higher scores meaning worse outcome	Baseline and Day 1 of each Cycle until Cycle 6 (each Cycle is 22 days)

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Adverse Events	Grade ≥2 clinical and Grade ≥3 laboratory adverse events assessed according to the CTCAE version 5 (Common Terminology Criteria for Adverse Events)	Baseline and Day 1 of each Cycle until Cycle 6 (each Cycle is 22 days)

Collaborators and Investigators

• Sponsor: Assistance Publique Hopitaux De Marseille
• Collaborators: The Hospital for Sick Children; Gustave Roussy, Cancer Campus, Grand Paris

Study record dates

Study Major Dates

• Study Start (Estimated): September 1, 2026
• Primary Completion (Estimated): January 1, 2029
• Study Completion (Estimated): July 1, 2029

Study Registration Dates

• First Submitted: July 22, 2026
• First Submitted That Met QC Criteria: July 27, 2026
• First Posted (Actual): July 31, 2026

Study Record Updates

• Last Update Posted (Actual): July 31, 2026
• Last Update Submitted That Met QC Criteria: July 27, 2026
• Last Verified: July 1, 2026

More Information

Terms related to this study

• Keywords: Cancer; Patient Reported Outcomes; Real-world evidence; Pediatric malignancies; Off-label therapies; Innovative cancer therapies
• Additional Relevant MeSH Terms: Nervous System Diseases; Neoplasms by Site; Nervous System Neoplasms; Neoplasms; Central Nervous System Neoplasms
• Other Study ID Numbers: RCAPHM25_0280; 2025-A02394-45 (Other Identifier: ANSM)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No